Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This is a Current Report (Form 8-K) filed by Cocrystal Pharma, Inc. on August 20, 2024, covering events occurring on August 19, 2024. The Company is a Delaware corporation with its principal executive offices in Bothell, WA. Its common stock trades on The Nasdaq Capital Market under the symbol "COCP".
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a corporate event rather than a financial statement.
Material Changes
There are no material financial changes reported in this filing. The primary event is the issuance of a press release announcing the Company's participation in upcoming investment conferences.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of conference participation. The filing does not contain specific financial guidance, updated outlooks, new risk factors, or contingencies. No unusual items were disclosed.
Key Facts for Investors to Verify
- Verify the specific dates and locations of the upcoming investment conferences mentioned in the press release (Exhibit 99.1).
- Confirm if the Company intends to present new clinical data or business updates at these events.
- Review the Company's most recent 10-Q or 10-K for actual financial performance metrics, as this 8-K contains none.